I enjoy working with emerging growth companies and their investors throughout the full life cycle of the company.
Sarah Kelley focuses her practice on advising entrepreneurs and emerging growth companies on a wide range of corporate matters, including formation and founder’s arrangements, early- and late-stage financings, commercial transactions, mergers and acquisitions, and general corporate governance matters. Her clients include both public and private companies as well as venture capital investors. Sarah works across industries, however she has significant experience representing life sciences, technology and cannabis companies. She also represents entrepreneurs as they develop their business plans and launch their companies.
Genialis in a $13M Series A financing led by Debiopharm Innovatoin Fund and Taiwania Capital to expand its proprietary ResponderID machine learning platform for clinical and translational research
Alloy Therapeutics in a number of transactions, including:
$42 million Series D financing round led by its existing investors 8VC and Mubadala Capital
$75.0 million Series C Financing led by 8VC, Presight Capital and Peter Thiel
As an investor in $21 million Series A Preferred Stock Financing of Vernal Biosciences, a manufacturer of high purity mRNA for research and clinical use
Zapata Computing, a quantum software company empowering enterprise teams to accelerate quantum solutions and capabilities, in closing its $38 million Series B financing, led by Comcast Ventures, Pitango and Prelude Ventures
Rental platform Zumper, Inc. in a $60 million Series D round led by e.ventures
Direct-to-consumer luxury shoe brand in connection with its Series B-1 Financing
Developer of crowdsourced repository for protocols in connection with its Series A Financing
MERGERS & ACQUISITIONS
Vesica Health, Inc., a precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer, in its $30.5 million sale to Photocure ASA (OSE: PHO), a leader in bladder cancer diagnostics.
Toposware, a developer of an interoperable blockchain ecosystem designed to tamper resistance and data privacy, in its sale to Turntable Merger Sub, Inc., a subsidiary of Polygon Labs Holdings (Cayman) Ltd.
Ellevation, a mission-driven software company focused exclusively on English Learners and the educators who serve them, in its sale to Curriculum Associates
Thermo Fisher Scientific Inc. (NYSE: TMO) in its acquisition of programmable dye platform pioneer Phitonex, Inc.
Entegris (Nasdaq: ENTG), a leader in specialty chemicals and advanced materials solutions for the microelectronics industry, in its acquisition of Sinmat for $75 million
New-Indy Containerboard, a joint-venture formed by the Kraft Group and Schwarz Partners, LP, in its acquisition of Shoreline Container
CAPITAL MARKETS
Sensata Technologies (NYSE: ST), a global sensors and electronic controls manufacturer, in connection with a Rule 144A offering of $750 million senior notes and an additional offering of $250 million senior notes
Entegris, Inc. (Nasdaq: ENTG) in a 144A offering of senior unsecured notes in an aggregate principal amount of $400 million
STRATEGIC TRANSACTIONS
Alloy Therapeutics, Inc. with the formation of Broadwing Bio LLC, a joint venture with Maze Therapeutics, Inc., to develop targeted antibody therapies for the treatment of ophthalmic diseases
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
